Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Amyloidosis is a systemic condition characterized by multiple organs involvement. A multidisciplinary and multimodal approach in assessing patients is pivotal and recommended by the international scientific societies. Biomarkers represent an essential noninvasive tool to increase the suspicion of disease and orient further workup and clinical management of patients. This review provides an updated contemporary focus on the clinical use of biomarkers in cardiac amyloidosis, emphasizing their role in both the diagnostic and prognostic setting and discussing future perspective of emerging biomarkers. Copyright © 2024 Elsevier Inc. All rights reserved.

Citation

Andrea Lalario, Riccardo Saro, Gianfranco Sinagra, Marco Merlo, Aldostefano Porcari. Clinical Use of Biomarkers in Cardiac Amyloidosis. Heart failure clinics. 2024 Jul;20(3):283-294

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38844299

View Full Text